HPV Vaccine from Merck Shows Promising Results in Late Trials

Nov 04, 2013


An experimental vaccine from Merck & Co. appeared to provide broader protection against a cancer-causing virus than the company's Gardasil shot in clinical trials. Merck said the study results support its plan to submit the new vaccine, code-named V503, for U.S. regulatory approval by year's end, which could lead to market launch next year at the soonest. Some analysts expect its annual sales could exceed $1 billion. Read the full story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments